Recent news on Revlimid

Patients with myelodysplastic syndromes treated with Revlimid are ...  -  May 20, 2007
News-Medical.net,New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS)

Myelodysplastic patients treated with Revlimid living longer  -  May 17, 2007
Antara (press release),Tampa, Florida (ANTARA News/PRNewswire-AsiaNet) - New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood

Study Continues to Show Patients With Myelodysplastic Syndromes ...  -  May 17, 2007
PR Newswire (press release),TAMPA, Fla., May 17 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known

Study Continues to Show Patients With Myelodysplastic Syndromes ...  -  May 17, 2007
CNW Telbec (Communiqués de presse),Breakthrough data presented at the meeting showed that Revlimid, or lenalidomide, can provide long-term survival benefit and prevent disease progression in

UPDATE 3-Celgene 1st-qtr profit up but Revlimid sales light  -  May 3, 2007
Reuters.uk,Revenue rose 61.4 percent to $293.4 million, driven by sales of Revlimid, which came in at $146.2 million. Analysts, however, had on average expected

Trial Therapy Given to All  -  May 21, 2007
NJBIZ,Revlimid is approved by the US Food and Drug Administration for combined use with dexamethasone as a treatment for patients with multiple myeloma who have

The International Myeloma Foundation Reports Positive Shift In ...  -  May 15, 2007
PR Newswire (press release),...-Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID(R) with Low Dose Steroids in Myeloma- -Experts Consider Novel Agents

The International Myeloma Foundation Reports Positive Shift In ...  -  May 15, 2007
PR Newswire (press release),Based on the findings, the data safety monitoring committee recommended all patients in the study be moved to a regimen of REVLIMID with low- dose

Celgene Reports First Quarter Record Operating Performance and ...  -  May 3, 2007
PR Newswire (press release),The National Cancer Institute Reported ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) With REVLIMID Plus Low-Dose Dexamethasone Suggests

Market Report -- In Play (CELG)  -  May 16, 2007
MSN MoneyCelgene says SWOG Phase III newly diagnosed multiple myeloma trial closed and patients given choice to switch to Revlimid plus Dexamethasone Co announces

Cancer patients offered new hope  -  May 17, 2007
Melbourne Herald Sun,Though it will be at least two years before Revlimid is assessed by the Therapeutic Goods Administration for use in Australia, six Victorian hospitals have

Celgene triples earnings from year-ago  -  May 3, 2007
Newark Star Ledger,Overhead costs increased as the company prepared for a European launch of Revlimid later this year. Celgene completed what it called a state-of-the-art

Sales Surge Not Enough for Celgene  -  May 3, 2007
TheStreet.comSales of Celgene's top product Revlimid more than quadrupled to $146 million. However, according to Reuters, which cited a research report,

US biotech drug spending rises while Congress debates over ...  -  26 Apr 2007
BiopharmaReporter.com,...which was driven by new treatments including three new drugs introduced in 2006 - Celgene's Revlimid (lenalidomide) for multiple myeloma and Pfizer's

Biotech Drug Spending Increases 21 Percent Even as Growth in Rx ...  -  26 Apr 2007
dBusinessNews St. Louis (press release),...increase in spending at 39.5 percent, which was driven by new treatments including three new drugs introduced in 2006 (Nexavar®, Revlimid® and Sutent®).

Celgene Revlimid drug trial temporarily suspended  -  Apr 11, 2007
ReutersO: Quote, Profile, Research) cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, which was running the

Revlimid Trial Temporarily Stopped  -  Apr 11, 2007
Cancerpage.com,BOSTON APR 11, 2007 (Reuters) - A trial of Celgene Inc.'s cancer drug Revlimid was halted to amend the protocol so that patients can be switched to a

Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for ...  -  Apr 5, 2007
Drug Newswire (press release),We are fully committed to deliver REVLIMID to patients in need throughout the EU," said Aart Brouwer, President of Celgene International.

Low-dose Dexamethasone plus Revlimid® Improves Survival over High ...  -  Apr 5, 2007
Cancer Consultants (press release),Revlimid, an immunomodulatory agent, fights cancer through several biological mechanisms, many of which are still being evaluated. One action Revlimid uses

Celgene says Revlimid data shows improved cancer survival rate  -  Apr 4, 2007
MarketWatch...said Wednesday that preliminary late-stage trial results for the use of its Revlimid with a lower-dose steroid in new bone-marrow cancer patients suggest a

Use of Celgene's Revlimid drug may expand  -  Apr 5, 2007
NorthJersey.com,SUMMIT -- Celgene Corp. says its thalidomide derivative Revlimid may help patients newly diagnosed with a blood cancer live longer, suggesting use of the

Celgene Says Survival Edge Found in Revlimid Study  -  Apr 4, 2007
Reuters.uk,O: Quote, Profile , Research) said on Wednesday that a review of early results from a large blood-cancer study found its Revlimid, used with a low dose of a

Celgene Shares Jump on Revlimid Outlook  -  Apr 5, 2007
Houston Chronicle,NEW YORK — Shares of biopharmaceutical company Celgene Corp. jumped Thursday on positive news that its cancer treatment Revlimid could be beneficial for

Drug Revlimid Extends Life Of Blood Cancer Patients  -  Apr 5, 2007
E Canada Now,Boston (eCanadaNow) - A new study on a drug known as Revlimid from Celgene Corp. has been found to help newly diagnosed patients with blood cancer live far

Revlimid Combo Designed to Treat Multiple Myeloma  -  Apr 5, 2007
Dog Flu Diet and Diseases,The drug is known as Revlimid and was first approved for anemia, but has now shown great promise in the treating of multiple myeloma.

Celgene:Survival Help Seen With Revlimid  -  Apr 4, 2007
Forbes,Drug maker Celgene Corp. said Wednesday a clinical cancer research organization suggested the combination of Revlimid and lower doses of a steroid could

The International Myeloma Foundation Says Recommendation for ...  -  Mar 30, 2007
Drug Newswire (press release),REVLIMID is the newest of a group of treatments together called novel therapies that are changing the course of treatment for myeloma, the second most

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03 ...  -  Apr 4, 2007
Earthtimes.orgREVLIMID (lenalidomide) is approved by the US Food and Drug Administration for use as a treatment in combination with standard-dose dexamethasone for

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03 ...  -  Apr 4, 2007
PR-Inside.com (Pressemitteilung),REVLIMID is also approved for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS)

Analysis: Street mixed on Celgene's drug  -  Apr 5, 2007
United Press InternationalCelgene's Revlimid appears to improve survival in multiple myeloma patients when used with a low-dose course of dexamethasone, but analysts were split

Analysis: Street mixed on Celgene's drug  -  Apr 5, 2007
United Press InternationalWASHINGTON, April 5 (UPI) -- Celgene's Revlimid appears to improve survival in multiple myeloma patients when used with a low-dose course of dexamethasone,

Celgene drug trial suspended to alter protocol  -  Apr 11, 2007
ReutersO: Quote, Profile, Research) cancer drug Revlimid was halted to amend the protocol so that patients can be switched to a regimen that has recently been

New Life-extending Drugs Drive Revenues in the US Multiple Myeloma ...  -  Apr 17, 2007
Newswire Today (press release),Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade—all fostering an unprecedented growth in the US

The International Myeloma Foundation Says New Clinical Trial ...  -  Apr 4, 2007
PR Newswire (press release),Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID(R) and other Drugs in Newly Diagnosed Myeloma

Celgene Cancer Drug Trial Halted - Analyst  -  Apr 11, 2007
CNBC,...cancer drug Revlimid was halted to amend the protocol so that patients can be switched to a regimen that has recently been shown to improve survival,

New Clinical Trial Results Could Improve Survival While Reducing ...  -  Apr 5, 2007
eMaxHealth.com,However, interim findings from a large ongoing clinical trial of REVLIMID plus dexamethasone in newly diagnosed patients, suggest lowering the "dex" dose

New Life-extending Drugs Drive Revenues in the US Multiple Myeloma ...  -  Apr 16, 2007
PR Newswire (press release),Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade -- all fostering an unprecedented growth in the US

Celgene stock rises amid drug trial data speculation  -  Apr 3, 2007
ReutersO: Quote, Profile, Research) rose more than 3 percent on Tuesday amid speculation that a clinical trial of its cancer drug Revlimid is being stopped early

Celgene Stock Rises Amid Drug Trial Data Speculation  -  Apr 3, 2007
Reuters.uk,O: Quote, Profile , Research) rose more than 3 percent on Tuesday amid speculation that a clinical trial of its cancer drug Revlimid is being stopped early

Zacks Analyst Blog Highlights: DR Horton, Lennar, Cost Plus and ...  -  Apr 11, 2007
Business Wire (press release),Its leading products are Thalomid (thalidomide) and Revlimid. Thalomid is an immunomodulatory agent with multiple-use potential.

Out of the Gate: Celgene rises  -  Apr 4, 2007
BusinessWeekCelgene Corp. stock gained ground in early trading Wednesday after a research group said its drug Revlimid could improve survival for patients with multiple

Out of the Gate: Celgene Rises  -  Apr 4, 2007
MSN MoneyNEW YORK (AP) - Celgene Corp. stock gained ground in early trading Wednesday after a research group said its drug Revlimid could improve survival for

Celgene Drug Trial Suspended to Alter Protocol  -  Apr 11, 2007
Therapeutics Daily (subscription) (press release),BOSTON (Reuters) - A trial of Celgene Inc.'s cancer drug Revlimid was halted to amend the protocol so that patients can be switched to a regimen that has

Celgene cancer drug better with less chemotherapy  -  Apr 4, 2007
Newark Star Ledger,Celgene yesterday said preliminary results of a key clinical trial for patients with multiple myeloma showed its blood cancer treatment Revlimid produced

Celgene "buy"  -  Apr 4, 2007
newratings.com...towards a survival benefit for low-dose dex/Revlimid combination, as compared to the standard-dose dex/ Revlimid in the front-line multiple myeloma.

Celgene stock rises amid drug trial data speculation  -  Apr 4, 2007
Therapeutics Daily (subscription) (press release),A trial known as ECOG-E4A03 is testing Revlimid in newly diagnosed patients with the bone marrow cancer multiple myeloma, in combination with either a high

NEW YORK (CNNMoney.com) -- Some of Wednesday's most actively ...  -  Apr 11, 2007
CNNMoney.comCelgene's (down $0.91 to $57.13, Charts) trial of its cancer drug Revlimid was temporarily suspended as of April 4, according to the group running the

Celgene rebounds after initial drop  -  Apr 11, 2007
ReutersAccording to a Lazard Capital Markets analyst Matthew Osborne, a trial of Celgene's cancer drug, Revlimid, was halted to amend the protocol so that patients

Analysis: Surge forecast for Pharmion drug  -  Mar 30, 2007
United Press InternationalIn addition to being the only drug approved for first-line, it will probably have a significant cost advantage over Celgene's Revlimid and Millennium's

Study results alter treatment for deadly form of cancer  -  Apr 5, 2007
Post-Bulletin,Oral lenalidomide (Revlimid) and low-dose dexamethasone (Decadron). • Oral lenalidomide and high-dose dexamethasone (standard therapy).

Celegne "market outperform"  -  Apr 5, 2007
newratings.comFurther catalysts for Celegne’s revenue acceleration in 2007 include European approval, pricing and the final launch of Revlimid in MDS and myeloma in the

Good news for newly diagnosed multiple myeloma patients  -  Apr 4, 2007
Post-Bulletin,Oral lenalidomide (Decadron) and low-dose dexamethasone (Revlimid). • Oral lenalidomide and high-dose dexamethasone (standard therapy).

Celgene shares give back Friday's gains  -  27 Mar 2007
BusinessWeekShares of biotechnology company Celgene Corp. on Monday gave back the modest gains made Friday when the company reported that its drug Revlimid received a

Celgene "buy"  -  27 Mar 2007
newratings.com...the analysts mention that the EMEA's Committee for Medicinal Products for Human Use issued a positive opinion for Revlimid for myeloma.

Celgene's thalidomide-derived Revlimid gets European nod  -  Mar 26, 2007
Pharma Times (subscription),US drugmaker Celgene Corp has received a recommendation from the European Medicine Agency's advisory panel for approval of its oral cancer drug Revlimid,

Oral cancer drug REVLIMID receives positive opinion  -  Mar 25, 2007
Antara (press release),We are fully committed to deliver REVLIMID to patients in need throughout the EU," said Aart Brouwer, President of Celgene International.

The International Myeloma Foundation Says Recommendation For ...  -  Mar 24, 2007
Medical News Today (press release),REVLIMID is the newest of a group of treatments together called novel therapies that are changing the course of treatment for myeloma, the second most

Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for ...  -  Mar 23, 2007
PipelineReview.com (press release),Celgene Corporation (Nasdaq: CELG) announced today that its innovative oral cancer drug REVLIMID (lenalidomide) has received a positive opinion from the

Questions and Answers on the Positive Opinion for Revlimid  -  Mar 23, 2007
PharmaLive.com (press release),Because Revlimid contains an active substance that has a chemical structure that resembles thalidomide, a number of measures have been taken to minimise any

Celgene's Revlimid Gets European Nod  -  Mar 23, 2007
Forbes,Biotechnology company Celgene Corp. said Friday it received a positive recommendation from European regulators for Revlimid as a combination treatment for

Committee for Medicinal Products for Human Use Summary of Positive ...  -  Mar 23, 2007
PharmaLive.com (press release),Revlimid was designated as an orphan medicinal product on 12 December 2003. The applicant for this medicinal product is Celgene Europe Limited.

Correction: Celgene Stock Movement Story  -  Mar 23, 2007
Forbes,...s stock movement, The Associated Press misstated a UBS Investment Research analyst's forecast for approval of Celgene's drug candidate Revlimid.

Market Report -- In Play (CELG)  -  Mar 23, 2007
MSN MoneyCelgene confirms oral cancer drug Revlimid receives positive opinion for treatment of multiple myeloma from european medicines agency Co confirms that its

Meeting Highlights From The Committee For Medicinal Products For ...  -  Mar 23, 2007
Medical News Today (press release),The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Revlimid (lenalidomide), from Celgene Europe, for the treatment

ImClones spikes on Amgen news  -  Mar 23, 2007
Newark Star Ledger,Celgene yesterday said it is step closer to winning approval to sell Revlimid in Europe as a second-line therapy for multiple myeloma.

Celgene Shares Edge Down  -  Mar 22, 2007
Forbes,Shares of Celgene Corp. edged down Thursday, but an analysts issued a bullish client note, citing the company's multiple myeloma drug candidate Revlimid.

Celgene Shares Edge Down  -  Mar 22, 2007
Houston Chronicle,UBS Investment Research analyst Maged Shenouda expects Revlimid to be approved for treatments of relapsed/refractory multiple and myelodysplastic syndrome

Pharmacy: Cancer care can leave bankrupt  -  Mar 25, 2007
Houston Chronicle,A year's treatment with Revlimid could reach more than $60000. When it is used in combination with another new cancer drug called Velcade, the annual bill

Celgene's oral cancer drug gets EU panel recommendation  -  Mar 23, 2007
ReutersThe recommendation is for use of the drug, Revlimid, in combination with dexamethasone, the company said in a statement.

Celgene's oral cancer drug gets EU panel recommendation  -  Mar 23, 2007
ReutersThe recommendation is for use of the drug, Revlimid, in combination with dexamethasone, the company said in a statement. (Reporting by Hari Kumar in

Celgene "neutral weight," estimates reduced  -  Mar 19, 2007
newratings.comIn a research note published this morning, the analyst mentions that the 2007 sales estimate for Revlimid has been reduced from $911 million to $828 million

Crash Insurance  -  Mar 4, 2007
New York Magazine,Celgene, like Genentech, has invented a drug, Revlimid, meant initially for bone-marrow cancer, that could turn out to be used for many other hard-to-beat

Analysis: Amgen's pain is ImClone's gain  -  Mar 23, 2007
Science Daily (press release)Analysis: Celgene's Revlimid looks strong (December 11, 2006) -- Data being presented this week should help drive sales of Celgene's Revlimid, but analysts

Analyst initiations 3-13-07: Celgene, CNET Networks & Transocean ...  -  Mar 13, 2007
Blogging StocksThe firm believes Revlimid can achieve the company's global sales of more than $3.2B by 2012 and feels the recent low $50's is an excellent share entry

Biotech in Review: A Perfect Storm for Genentech and Amgen  -  Mar 25, 2007
Seeking Alpha,Celgene (CELG) received a recommendation for approval of Revlimid in Europe. The drug would be indicated for patients with multiple myeloma who have

Myelodysplastic Syndromes  -  Mar 7, 2007
Cancer Focus,A person with a 5q- deletion may take Revlimid and live quite a long time with no transfusions, but make no mistake about it, if you do not visit the

Velcade®, Alkeran®, Prednisone and Thalomid® Effecive for Relapsed ...  -  Mar 23, 2007
Cancer Consultants (press release),Alkeran (200 mg/m2) supported by autologous stem cells and the development of new agents such as Thalomid), Revlimid® (lenalidomide) and Velcade.

Schwarzkopf: Finding cancer cure no ‘Impossible Dream’  -  Mar 16, 2007
Naples Daily News,Chief of Moffitt’s hemotologic malignancies division, List’s baby is now called Revlimid and has made significant dents in myelodysplastic syndromes (MDS)

Will Biotechs Pay the Price for Playing in the Big Leagues?  -  Mar 15, 2007
Seeking Alpha,Biotech blockbusters such as ImClone's (IMCL) Erbitux, Genentech's Avastin and Lucentis, Amgen's Vectibix, and Celgene's (CELG) Revlimid sell for around

Velcade® Safe and Effective for Patients with Multiple Myeloma and ...  -  Mar 15, 2007
Cancer Consultants (press release),...stem cells and the development of new agents such as Thalomid® (thalidomide), Revlimid® (lenalidomide), Doxil® (liposomal doxorubicin) and Velcade.

Prescription Drug Sales in USA +8% in 2006 to $275 Billion ...  -  Mar 10, 2007
Think & Ask,Lucentis™ (for macular degeneration) -- Pfizer’s Sutent® (for renal cell carcinoma) -- and Celgene’s Revlimid® (for transfusion-dependent anemia.)

IMS Health Reports US Prescription Sales Jump 8.3 Percent in 2006 ...  -  Mar 9, 2007
PharmaLive.com (press release),Lucentis(TM) (for macular degeneration); Pfizer's Sutent(R) (for renal cell carcinoma); and Celgene's Revlimid(R) (for transfusion-dependent anemia).

News For Your Web Site  -  Mar 9, 2007
dBusinessNews Hartford (press release),Lucentis™ (for macular degeneration); Pfizer’s Sutent® (for renal cell carcinoma); and Celgene’s Revlimid® (for transfusion-dependent anemia).

IMS Health Reports 8.3% Growth In US Prescription Sales For 2006 ...  -  Mar 8, 2007
Trading Markets,Genentech's Lucentis for macular degeneration, Pfizer's Sutent for renal cell carcinoma and Celgene's Revlimid for transfusion-dependent anemia are

From the analyst's couch: Multiple myeloma therapies  -  Mar 2, 2007
Nature.com (subscription),Lenalidomide (Revlimid; Celgene) is the most advanced IMiD and was approved by the FDA in June 2006 for the treatment of patients with MM that have failed

Wall Street split on Amgen  -  Mar 2, 2007
Monsters and Critics.com,...big-cap dollars and put it in there,' he said, adding that the company has the best growth of all big-cap biotechs with its recent Revlimid rollout.

Analysis: Wall Street split on Amgen  -  Mar 2, 2007
United Press International...big-cap dollars and put it in there," he said, adding that the company has the best growth of all big-cap biotechs with its recent Revlimid rollout.

Sector Wrap: Biotechnology  -  Feb 27, 2007
Forbes,Nonetheless, the maker of bone marrow cancer treatment Thalomid and the blood disease treatment Revlimid shows a 48.8 percent gain over the past 52 weeks.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional